More than 2,200 ophthalmologist and optometry practices in the United States now employ the LACRIFILL rabbit gel in their patients undergoing cataract or refractive surgery, as well as to relieve symptoms and reduce dependence on eye drops in patients with dry eye syndrome. So far, more than 130,000 patients have been treated with this innovative therapy.
In the company's recent survey on patient satisfaction, 96% of respondents who had undergone cataract surgery in the past six months, as well as 91% of all patients surveyed, said their eyes felt better thanks to LACRIFILL Canalicular Gel.
“Ophthalmology professionals are aware that the AAO offers an excellent opportunity to learn about the latest advances in ophthalmology and how they benefit their patients. We are pleased to introduce data demonstrating the benefits of using LACRIFILL Canalicular Gel, including higher well-being and more stable vision in both postoperative applications and the treatment of the dry eye," Dr. med said. Jai G. Parekh, MBA, Chief Commercial Officer of Nordic Pharma, Inc. “Patients with the dry eye also report that they rely less on prescription and over-the-counter eye drops. We look forward to sharing this and more details of our latest data with the participants of the AAO."
Monitoring the surface of the eye after cataract or refractive surgery is vital for supporting postoperative recovery, patient satisfaction and quality of life.
“The vast majority – 83% – of patients who have undergone surgery in the last six months and had received at least one treatment with LACRIFILL reported lower symptoms. This relief is of great importance. And since LACRIFILL Canalicular Gel is indicated for an application duration of up to six months, this postoperative benefit can be maintained," Dr. med explained. David Szynkarski of the Mann Eye Institute based in Houston, Texas. “The Mann Eye Institute has set itself the task of making groundbreaking advances in ophthalmology. The LACRIFILL Canalicular Gel allows us to provide better care to our patients and has contributed to the growth of our practice through excellent treatment outcomes."
During the AAO, visitors can visit the stand of Nordic Pharma (No. 3136) on Saturday, the 10th. October, and on Sunday, the 11th. October, from 10:00 to 16:00, observe how ophthalmologists and opticians use the LACRIFILL Canalicular Gel. Participants also have the opportunity to place orders directly at the booth.
About SEVER Life Sciences B.V.
SEVER Life Sciences is a global, privately held holding company in the field of specialty pharmaceuticals that is committed to enabling people around the world to live a better life. Headquartered in the Netherlands, SEVER Life Sciences brings together three different but complementary companies that offer a wide range of products, services in pharmaceutical development and delivery technologies.
Nordic Pharma, Inc.
Nordic Pharma, Inc., a subsidiary of Sever Life Sciences B.V., maintains partnerships with established global biopharmaceutical companies and has a unique position to leverage its expertise in the market launch of medical devices and sterile manufacturing.
Safe Harbor clause:
This press release contains forward-looking statements, including, but are not limited to, statements regarding the business development of SEVER Life Sciences / Nordic Pharma and the implementation of the strategic initiatives of SEVER Life Sciences / Nordic Pharma. As these statements reflect the current views, expectations and beliefs of SEVER Life Sciences/Nordic Pharma regarding future events, these forward-looking statements are fraught with risks and uncertainties that could cause actual developments and results to differ materially from the expectations of SEVER Life Sciences/Nordic Pharma. These factors include general market conditions, regulatory developments, changes in the financial situation of third parties working with SEVER Life Sciences / Nordic Pharma, and other factors that could influence the business and financial performance of SEVER Life Sciences / Nordic Pharma. SEVER Life Sciences / Nordic Pharma assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or other reasons.
